Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

Completed · Phase 3 · Has a placebo group

Conditions studied: Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia

In brief

The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).

Key facts

Study ID: NCT00106691
Run by: GTx
People needed: 1589
Starts: 2005-01-01
Expected to finish: 2010-02-01
Last updated by the study team: 2023-06-12

Who can join

Age: 30 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Give voluntary signed informed consent in accordance with institutional policies
Be male, aged ≥ 30 years
Have a diagnosis of high grade PIN from any previous prostate biopsy. The diagnosis of high grade PIN must be confirmed by the central pathologist
Have had a prostate biopsy in the last 6 months with a minimum of 10 cores that shows no evidence of cancer as confirmed by the central pathologist; OR, have had 2 prostate biopsies (each with a minimum of 6 cores) in the 12 months prior to screening with at least one of the biopsies occurring within 6 months prior to the screening visit. Both biopsies should have no evidence of cancer as confirmed by the central pathologist
Have a serum PSA of ≤ 10 ng/mL
Agree to provide tablet containers for tablet counts and to complete a daily diary of study drug intake
Agree to use an effective method of contraception, if the partner is of child-bearing age, while on study and for 30 days after the last dose of study medication
Have adequate bone marrow, liver and renal function:
White Blood Cell (WBC) Count ≥ 3,000/mm3;
Platelet Count ≥ 100,000/mm3;
Bilirubin ≤ 1.5 mg/dL;
AST and ALT < 2x upper limit of normal;
Serum Creatinine ≤ 2.0 mg%

You may not qualify if…

Previous exposure to toremifene citrate
Have evidence of prostate cancer (local, regional and/or distal metastasis)
Have any history of other malignancies (Exceptions include non-melanoma skin cancer or other cancer that has no evidence of tumor reoccurrence 5 years after definitive treatment).
Have active systemic viral, bacterial, or fungal infections requiring treatment
Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
Concurrently being treated with other investigational agents or have participated in an investigational study within 60 days prior to screening
Currently taking dutasteride. Subject is eligible if he stops dutasteride for a total washout of 90 days prior to the Screening Visit and agrees not to use dutasteride for the duration of the study.
Have previously taken finasteride for greater than two years
Currently taking finasteride. Subject is eligible if he stops finasteride for a total washout of 30 days prior to the Screening Visit and agrees not to use finasteride for the duration of the study.
Currently taking testosterone or testosterone-like supplements, such as dehydroepiandrosterone (DHEA). Subject is eligible if he stops these agents for a total washout of 30 days prior to the Screening Visit and agrees not to use these agents for the duration of the study.
Have a history of taking PC-SPES within the past two years.
Currently taking herbal medicine or dietary supplements for prostate health, such as Saw Palmetto (also known as Serenoa Repens).
Subject is eligible if he stops these agents for a total washout of 30 days prior to taking the first dose of study drug and agrees not to use these agents for the duration of the study.
Lycopene, vitamin E and selenium are not prohibited and no washout is required. However, vitamin E intake should be limited to less than 400 i.u. per day.
Have a history of thromboembolic event or disease including deep vein thrombosis, pulmonary embolus, or thrombotic stroke
History of chronic hepatitis or cirrhosis

Where it is running

Coastal Clinical Research — Mobile, Alabama, United States
Hope Research Inst. — Phoenix, Arizona, United States
Arkansas Urology — Little Rock, Arkansas, United States
San Bernardino Urological Associates Medical Group — San Bernardino, California, United States
Western Clinical Research, Inc. — Torrance, California, United States
Urology Research Options — Aurora, Colorado, United States
Urology Associates, P.C. — Denver, Colorado, United States
The Urology Center of Colorado — Denver, Colorado, United States
Connecticut Surgical Group — Hartford, Connecticut, United States
Urological Associates of Bridgeport — Trumbull, Connecticut, United States
Connecticut Clinical Research — Waterbury, Connecticut, United States
South Florida Medical Research — Aventura, Florida, United States
Atlantic Urological Associates — Daytona Beach, Florida, United States
Southwest Florida Urologic Associates — Fort Myers, Florida, United States
Advanced Research Institute — New Port Richey, Florida, United States
UroSearch — Ocala, Florida, United States
Central Florida Urology Group/ UroSearch — Ocala, Florida, United States
Florida Foundation for Healthcare Research — Ocala, Florida, United States
Winter Park Urology Associates — Orlando, Florida, United States
Panama City Urological Center — Panama City, Florida, United States
Demaur Clinical Research Center — Pembroke Pines, Florida, United States
DMI Research — Pinellas Park, Florida, United States
Urology Consultants — Pinellas Park, Florida, United States
Florida Urology Specialists — Sarasota, Florida, United States
Medical Affiliated Research Ctr. — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.